Press Releases July 23, 2026 08:00 AM

Lifetime Brands Announces Second Quarter 2026 Financial Results Release Date

Lifetime Brands schedules release of Q2 2026 financial results and conference call

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
LCUT

Lifetime Brands, a global provider of branded kitchenware, tableware, and home products, announced that it will release its second quarter 2026 financial results on August 6, 2026, before the market opens. The company will also hold a conference call to discuss these results on the same day.

Lifetime Brands Announces Second Quarter 2026 Financial Results Release Date
LCUT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Announcement of Q2 2026 financial results release date on August 6, 2026.
  • Scheduled conference call to discuss financial results with investors and analysts.
  • Lifetime Brands markets a diverse portfolio of well-known household and kitchenware brands, impacting consumer goods and retail sectors.

GARDEN CITY, N.Y., July 23, 2026 (GLOBE NEWSWIRE) -- Lifetime Brands, Inc. (Nasdaq: LCUT), a leading global provider of branded kitchenware, tableware and other products used in the home, will release its second quarter 2026 financial results before market open on Thursday, August 6, 2026. The Company will host a conference call to discuss the results on the same day at 11:00 a.m. Eastern Time.

Investors and analysts may access the live conference call by dialing 1-844-826-3035 (USA) or 1-412-317-5195 (International). In addition, a live webcast of the conference call will be accessible through the investor relations website here.

For those who cannot listen to the live broadcast, an audio replay of the webcast will be available on the Company’s investor relations website at https://lifetimebrands.gcs-web.com/ or via telephone replay by dialing 1-844-512-2921 (USA) or 1-412-317-6671 (International) and entering access code 10209750.

About Lifetime Brands, Inc.
Lifetime Brands is a leading global designer, developer and marketer of a broad range of branded consumer products used in the home. The Company markets its products under well-known kitchenware brands, including Farberware®, KitchenAid®, Sabatier®, Amco Houseworks®, Chef’n® Chicago™, Metallic, Copco®, Fred® & Friends, Houdini™, KitchenCraft®, Kamenstein®, La Cafetière®, MasterClass®, Misto®, Swing-A-Way®, Taylor® Kitchen, Rabbit®, and Dolly®; respected tableware and giftware brands, including Mikasa®, Pfaltzgraff®, Fitz and Floyd®, Empire Silver™, Gorham®, International® Silver, Towle® Silversmiths, Wallace®, Wilton Armetale®, V&A®, Royal Botanic Gardens Kew®, Year & Day®, Dolly®, Royal Leerdam®, and ONIS®; and valued home solutions brands, including BUILT NY®, S’well®, Taylor® Bath, Taylor® Kitchen, Taylor® Weather, Elements®, Planet Box®, and Dolly®. The Company also provides exclusive private label products to leading retailers worldwide.

The Company’s corporate website is www.lifetimebrands.com.

Contacts:
Lifetime Brands, Inc.
Laurence Winoker, Chief Financial Officer
516-203-3590
investor.relations@lifetimebrands.com

or

MZ North America
Shannon Devine
Main: 203-741-8811
LCUT@mzgroup.us


Risks

  • Financial performance uncertainty ahead of the Q2 results may cause stock volatility.
  • Potential market reaction depends on the actual earnings and financial indicators disclosed in the release.
  • Broader economic factors impacting consumer discretionary spending could affect the company's future results.

More from Press Releases

HP Googlebook 14 Brings Premium Craftsmanship to Google’s Newest Connected Platform Sep 21, 2026 Kratos and GE Aerospace Achieve Significant Program Milestone with Successful Ignition of GEK800 Turbofan Cruise Missile Propulsion System Sep 21, 2026 Microchip Technology Completes Acquisition of Hailo Sep 21, 2026 Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum Sep 21, 2026 NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) Sep 21, 2026